Cidara Therapeutics, Inc. CDTX 深 滬
已收盤 01-07 16:00:00 美东时间
221.38
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 221.38
- 總市值 69.74亿
- 52周最高 221.42
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 15.22
- 委 比 0.00%
- 總股本 3150.43万
- 歷史最高 382.60
- 量 比 0
- 振 幅 0.00%
- 歷史最低 8.00
- 每 手 1
- 風險率 67.35%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多UPDATE 2-Merck's 2026 outlook clouds upbeat fourth-quarter results
UPDATE 2-Merck's 2026 outlook clouds upbeat fourth-quarter results Co expects 2026 sales of $65.5 bln-$67 bln vs analysts' estimate $67.6 bln Reports Q4 sales of $16.4 bln, with Keytruda contributing $8.37 bln CEO Davis says still on the lookout for deals Adds analyst comments in paragraphs 5 and 10
02-03 19:40
UPDATE 1-Merck forecasts 2026 sales below estimates on patent losses
UPDATE 1-Merck forecasts 2026 sales below estimates on patent losses Expects 2026 sales $65.5 bln-$67 bln; analysts estimating $67.6 bln Q4 sales were $16.4 bln, with Keytruda contributing $8.37 bln CEO Davis says still on the lookout for deals Adds shares in paragraph 3 By Michael Erman Feb 3 (Reut
02-03 19:40
Merck Q4 revenue misses estimates on lower Gardasil demand
Merck Q4 revenue misses estimates on lower Gardasil demand Overview Pharmaceutical firm's Q4 revenue grew 5% but missed analyst expectations Adjusted EPS for Q4 beat analyst expectations Company highlighted progress in pipeline and acquisitions Outlook Merck anticipates 2026 sales between $65.5 bln
02-03 19:39
Merck & Co. meldet für das vierte Quartal 2025 ein den Aktionären zurechenbares Nettoergebnis von 2.963 Mio. USD, ein Rückgang um 21 Prozent
Merck & Co. meldet für das vierte Quartal 2025 ein den Aktionären zurechenbares Nettoergebnis von 2.963 Mio. USD, ein Rückgang um 21 Prozent Merck & Co. Inc. hat die Finanzergebnisse für das vierte Quartal sowie das Gesamtjahr 2025 veröffentlicht. Das den Aktionären zurechenbare Nettoergebnis belief
02-03 19:31
Merck posts Q4 diluted EPS of USD 1.19, down 20%
Merck posts Q4 diluted EPS of USD 1.19, down 20% Merck & Co. Inc. reported its financial results for the fourth quarter (Q4) and full year (FY) 2025. For Q4 2025, net income attributable to shareholders was USD 2.96 billion, with diluted earnings per share (EPS) of USD 1.19. For the full year 2025,
02-03 19:31
Merck forecasts 2026 sales below estimates on patent losses
Merck forecasts 2026 sales below estimates on patent losses Expects 2026 sales $65.5 bln-$67 bln; analysts estimating $67.6 bln Q4 sales were $16.4 bln, with Keytruda contributing $8.37 bln CEO Davis says still on the lookout for deals By Michael Erman Feb 3 (Reuters) - Merck & Co MRK.N on Tuesday f
02-03 19:30
不再迷惘的制药商：2025年并购额暴涨124%，巨头狂扫创新药资产
那些关于药品定价政策及可能侵蚀利润的关税措施的最坏担忧均未成真，行业焦虑情绪得到明显缓解。 智通财经APP获悉，下周，制药商们将赴旧金山出席摩根大通医疗健康年...
01-10 00:49
不再迷惘的制药商：2025年并购额暴涨124%，巨头狂扫创新药资产
下周，制药商们将赴旧金山出席摩根大通医疗健康年会，心态较2025年显著放松。回溯一年前，他们还对美国总统唐纳德·特朗普的政策走向感到困惑迷惘;如今，此前笼罩的诸...
01-09 21:50
Merck completes cash tender offer for Cidara Therapeutics
Merck (MRK) has finished its cash tender offer for all outstanding shares of Cidara Therapeutics (CDTX) at a price of $221.50 per Cidara share. The deal, announced in November, has a value of $9.2B. M...
01-07 20:28
Merck Completes Cash Tender Offer At Purchase Price Of $221.50 Per Share Of Common Stock Of Cidara Therapeutics
Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced the successful completion of the cash tender offer, through a subsidiary, for all the outstanding shares of common stock of Cidara
01-07 19:55
